Over 1,000 peer reviewed publications report the opportunity of the synergistic effect of radiotherapy and immune-oncology agents. The effect of sufficient levels of beta radiation on tissue is an inflammatory and immunogenic response followed by subsequent coagulative necrosis. The combination of inflammation and the immunogenic effect of beta radiation combined with an immune-oncology agent to synergistically acts to ‘unstealth’ the tumour region and stimulate an immune response. BetaGlue Therapeutics is pursuing the evaluation of this potentially powerful combination broadening the platform capability of YntraDose even further.
